Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus

The authors aimed to evaluate the efficacy and safety of obinutuzumab, a monoclonal antibody, in adults with active systemic lupus erythematosus (SLE) who were not experiencing proliferative or membranous lupus nephritis. In a phase 3 trial, obinutuzumab demonstrated a significantly higher response rate compared to placebo at week 52, achieving superior outcomes across multiple secondary endpoints, although adverse events were reported in both groups. Overall, the study concluded that obinutuzumab is an effective treatment option for active SLE.